Phase Advance AI

Phase Advance AI is a predictive technology company focused on transforming drug development by forecasting Phase III clinical trial outcomes immediately after the discovery phase. Powered by the proprietary Phase Advance Predictive Technology Platform™, the company builds complex, nonlinear mathematical models of disease progression in silico to accurately predict day-to-day responses at the individual patient level — even for drugs that have never entered a single animal or human subject. The platform has demonstrated 99.94% proven accuracy and is capable of delivering predictions for 10 molecules within approximately 3 months.

Phase Advance addresses one of the most costly challenges in the pharmaceutical industry: the fact that 97% of drug candidates fail after discovery, often only after spending up to $2 billion and 12–15 years in clinical development. With only 1 in 6,000 molecules driving a return on investment, Phase Advance's platform is designed to identify success or failure early — saving biopharma companies up to $2 billion and as many as 14 years in costs per drug program.

The Phase Advance Predictive Technology Platform™

• Built on nonlinear mathematical models of disease progression that reflect the natural, nonlinear functions of human biology
• Custom AI developed over decades to accelerate predictions by identifying patterns within individual patient responses to drugs
• Quantitatively maps the entire drug development process — from preclinical through clinical stages — before any preclinical work begins
• Predicts individual-patient-level clinical response rates, best biomarkers, optimal doses, and comparative drug performance

Key Forecasting Capabilities

• Optimal dose identification
• Optimal drug combination predictions
• Clinical trial endpoints — both before and after preclinical development
• Clinical trial design optimization
• Ethnic and genetic population-based predictions of efficacy and toxicity rates
• Lifetime models for determining optimal treatment start timing
• Predicted efficacy versus market-leading therapies
• Identification of molecular parameters to optimize for improved performance

Clients and Use Cases

• Contract Research Organizations (CROs): Optimized clinical trial design, ability to pre-test genetically diverse populations, reduced recruitment requirements, and lower risk for trial volunteers
• BioPharma Companies: Rank and prioritize molecules for advancement, optimize lead candidates to convert underperformers into viable drugs, predict performance versus standard of care, and support ethical placebo arm design for rare disease trials
• Investors: Identify high-potential molecules for investment, support due diligence processes, and predict competitive performance against other drugs in development
• AI Drug Discovery Firms: Predict performance of discovered molecules, rank and de-risk candidate libraries, and optimize predicted poor performers before further investment

By starting with rigorous scientific modeling of human biology and layering purpose-built AI on top, Phase Advance offers a fundamentally differentiated approach to drug development risk reduction — enabling earlier, more informed decisions across the entire pharmaceutical value chain.